Navigation Links
Regulus to Present at Future Leaders in the Biotech Industry Conference
Date:3/28/2013

LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20th Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT.  The conference is being held at the Millennium Broadway Hotel and Conference Center in New York City.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of each webcast will be archived on the Company's website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
2. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
3. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
4. Regulus to Present at Two Upcoming Investor Conferences
5. Regulus Appoints Mark G. Foletta to its Board of Directors
6. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
7. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
8. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
9. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
10. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2017)... Aug. 29, 2017 In a move that ... regulatory compliance for veterinary practices of all sizes, Cubex ... partnership that makes TITAN,s expertise in physical security, drug ... Cubex,s clients nationally. ... handling controlled substances is at risk today," said TITAN ...
(Date:8/28/2017)... 28, 2017   Aesculight ®, a division of LightScalpel ®, ... lasers. Built on over 20 years of American veterinary laser surgery innovation, ... Exclusive VetScalpel®Features and Enhancements ... is excising a tumor with his new VetScalpel laser. Dr. Duclos practices ... ...
(Date:8/25/2017)... 25, 2017   West Pharmaceutical Services, Inc. (NYSE: ... administration, announced that management will be presenting a West business ... Management will present at the Baird 2017 ... New York, N.Y. , at 3:10 p.m. ... Conference, at the Westin Boston Waterfront in Boston, ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 20, 2017 , ... “Psalms of Humidity”: is a fascinating depiction of daily ... readers one step closer to God. “Psalms of Humidity” is the creation of published ... been made within his life are the very same things that have shaped him ...
(Date:9/20/2017)... ... 2017 , ... “The Financial Favor of God; Second Edition”: a personal and ... is the creation of published author, Brooks Rathell. , “We typically hear about the ... about the financial favor of God. Not only does it exist, but it is ...
(Date:9/20/2017)... ... , ... “Monique”: is the story of Monique, whose mother’s deteriorating physical ... author, Colleen Crispi, has owned four beauty salons and written a book regarding the ... and cooking. , “The doctor’s office was only three blocks away, and she ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected ... own Ross A. Clevens, MD, FACS . The founder and medical director of ... Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He has ...
(Date:9/19/2017)... Alabama (PRWEB) , ... September 19, 2017 , ... ... customer success story on St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill ... St. Vincent’s Infusion Services enhanced service delivery and operations by leveraging PAPA Healthcare’s ...
Breaking Medicine News(10 mins):